TY - JOUR T1 - Network Meta-Analysis Comparing the Short and Long-Term Outcomes of Alternative Access for Transcatheter Aortic Valve Replacement JF - medRxiv DO - 10.1101/2021.09.06.21263150 SP - 2021.09.06.21263150 AU - Sagar Ranka AU - Shubham Lahan AU - Adnan K. Chhatriwalla AU - Keith B. Allen AU - Sadhika Verma AU - Pedro Villablanca Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/10/2021.09.06.21263150.abstract N2 - Objectives This study aimed to compare short- and long-term outcomes following various alternative access routes for transcatheter aortic valve replacement (TAVR).Methods Thirty-four studies with a pooled sample size of 30,986 records were selected by searching PubMed and Cochrane library databases from inception through 11th June 2021 for patients undergoing TAVR via 1 of 6 different access sites: Transfemoral (TF), Transaortic (TAO), Transapical (TA), Transcarotid (TC), Transaxillary/Subclavian (TSA), and Transcaval (TCV). Data extracted from these studies were used to conduct a frequentist network meta-analysis with a random-effects model using TF access as a reference group.Results Compared with TF, both TAO [RR 1.91, 95% CI (1.46–2.50)] and TA access [RR 2.12, 95%CI (1.84–2.46)] were associated with an increased risk of 30-day mortality. No significant difference was observed for stroke, myocardial infarction, major bleeding, conversion to open surgery, and major adverse cardiovascular or cerebrovascular events in the short-term (≤ 30 days). Major vascular complications were lower in TA [RR 0.43, (95% CI, 0.28-0.67)] and TC [RR 0.51, 95% CI (0.35-0.73)] access compared to TF. The 1-year mortality was higher in the TAO [RR of 1.35, (95% CI, 1.01–1.81)] and TA [RR 1.44, (95% CI, 1.14–1.81)] groups.Conclusion Non-thoracic alternative access site utilization for TAVR implantation (TC, TSA and TCV) is associated with similar outcomes to conventional TF access. Thoracic TAVR access (TAO and TA) is associated with increased short and long-term mortality.Competing Interest StatementSagar Ranka, Shubham Lahan, Michael Chiang, Sadhika Verma, and Pedro Villablanca have no competing interests. Adnan K. Chhatriwalla: Speakers Bureau: Abbott Vascular, Edwards Lifesciences, Medtronic Inc.; Proctor: Edwards Lifesciences, Medtronic Inc.; Consultant: Boston Scientific, Silk Road Medical; Research Grant: Boston Scientific Keith B. Allen: Institutional Research/Grant support: Edwards, Abbott, Medtronic, Boston Scientific; Speakers Bureau: Edwards Lifesciences, Medtronic Inc.; Proctor: Edwards Lifesciences, Medtronic Inc.; Consultant: Abbott, Edwards, Medtronic, Boston Scientific; (all payments are to the institution and none to me personally).Clinical TrialNAFunding StatementNo external funding was obtained for supporting this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Being a systematic review of existing literature, our study was exempt from IRB's approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in this manuscript has been extracted from already published articles. The authors declare that all supporting data are available within the article (and its online supplementary files). ER -